Table 4.

Multivariate Survival Analysis for Progression-Free Survival in Patients with KRAS Mutation

Variables	PFSa			PFSb
	HR	95% CI	P	HR	95% CI	P
KRAS G12C (with vs. without)	0.31	0.13–0.77	0.01	0.46	0.19–1.07	0.07
Age (≥60 vs.<60)	0.63	0.91–1	0.15	0.49	0.23–1.06	0.07
Smoke, (never vs. current/former)	1.202	0.46–3.62	0.62	2.58	0.84–7.87	0.10
c1st-line chemo	0.55	0.3–1	0.04	1.10	0.74–1.63	0.64

^a1st-line chemotherapy.

^bData on 1st-line and 2nd-line chemotherapy and the multivariate analysis were not available. PFS, progression-free survival; HR, hazard ratio; CI, confidence interval.

^c1st-line chemo included pemetrexed-, taxanes- and gemcitabine-based chemotherapy, nonpemetrexed chemotherapy as reference.